Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

GenomeWeb
genomeweb.com > cancer > roche-gets-fda-clearance-b-cell-lymphoma-test

Roche Gets FDA Clearance for B-Cell Lymphoma Test

2+ day, 22+ hour ago   (17+ words) GenomeWeb Roche Gets FDA Clearance for B-Cell Lymphoma Test...

GenomeWeb
genomeweb.com > diagnostics > tissue-based > digital-pathology > gnw-lunit-10x-collaboration-ai-pathology-20260910

10x Genomics to Use Lunit’s AI-Powered Pathology Platform for Oncology Biomarker Discovery

2+ day, 18+ hour ago   (26+ words) GenomeWeb 10x Genomics to Use Lunit’s AI-Powered Pathology Platform for Oncology Biomarker Discovery...

GenomeWeb
genomeweb.com > diagnostics > molecular > gnw-one-biosciences-breast-cancer-diagnostic-funding-20260910

One Biosciences, Institut Curie to Develop TNBC Single-Cell Dx Assay With €3.3M in French Funding

2+ day, 22+ hour ago   (32+ words) GenomeWeb One Biosciences, Institut Curie to Develop TNBC Single-Cell Dx Assay With €3.3M in French Funding...

GenomeWeb
genomeweb.com > business-news > regulatory > fda > clearance > gnw-radiopharmaceutical-full-life-phase-i-lung-cancer-20260910

Radiopharm Firm Full-Life to Launch Phase I Lung Cancer Trial in US, Australia

2+ day, 23+ hour ago   (27+ words) GenomeWeb Radiopharm Firm Full-Life to Launch Phase I Lung Cancer Trial in US, Australia...

GenomeWeb
genomeweb.com > precision-oncology > context-therapeutics-begins-phase-i-trial-bispecific-antibody-cldn6-positive

Context Therapeutics Begins Phase I Trial of Bispecific Antibody in CLDN6-Positive Tumors

3+ day, 23+ hour ago   (69+ words) GenomeWeb Context Therapeutics Begins Phase I Trial of Bispecific Antibody in CLDN6-Positive Tumors NEW YORK – Context Therapeutics on Wednesday said it began treating patients in a Phase I trial of its claudin 6 (CLDN6)- and CD3 T-cell-engaging bispecific antibody, CTIM-76, in CLDN6-positive…...

GenomeWeb
genomeweb.com > drug-development > clinical-trial > gnw-brainchild-car-t-pediatric-glioma-20260909

BrainChild Raises $116M for Newly Launched CAR T Trial for Pediatric Glioma

3+ day, 23+ hour ago   (65+ words) GenomeWeb BrainChild Raises $116M for Newly Launched CAR T Trial for Pediatric Glioma NEW YORK – Backed by $116 million in new financing, BrainChild Bio is starting a new trial of a CAR T-cell therapy for pediatric brain tumors that it hopes…...